Education

Ph.D., McMaster University

Current position

Senior Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute
Professor, Depts. of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa

Publications

1. Arulanandam, R., Batenchuk, C., Varette, O., Zakaria, C., Garcia, V., Forbes, N. E., Davis, C., Krishnan, R., Karmacharya, R., Cox, J., Sinha, A., Babawy, A., Waite, K., Weinstein, E., Falls, T., Chen, A., Hamill, J., De Silva, N., Conrad, D. P., Atkins, H., Garson, K., Ilkow, C., Kaern, M., Vanderhyden, B., Sonenberg, N., Alain, T., Le Boeuf, F., Bell, J. C.* and Diallo, J. S.* (2015). Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun 6: 6410.
   
2. Ilkow, C. S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., Cousineau, S., Falls, T., Jennings, V. A., Boileau, M., Bellamy, D., Bastin, D., de Souza, C. T., Alkayyal, A., Zhang, J., Le Boeuf, F., Arulanandam, R., Stubbert, L., Sampath, P., Thorne, S. H., Paramanthan, P., Chatterjee, A., Strieter, R. M., Burdick, M., Addison, C. L., Stojdl, D. F., Atkins, H. L., Auer, R. C., Diallo, J. S., Lichty, B. D. and Bell, J. C. (2015). Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med 21(5): 530-536.
   
3. Evgin, L., Acuna, S. A., Tanese de Souza, C., Marguerie, M., Lemay, C. G., Ilkow, C. S., Findlay, C. S., Falls, T., Parato, K. A., Hanwell, D., Goldstein, A., Lopez, R., Lafrance, S., Breitbach, C. J., Kirn, D., Atkins, H., Auer, R. C., Thurman, J. M., Stahl, G. L., Lambris, J. D., Bell, J. C.1 and McCart, J. A.* (2015). Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther 23(6): 1066-1076.
   
4. Arulanandam, R., Batenchuk, C., Angarita, F. A., Ottolino-Perry, K., Cousineau, S., Mottashed, A., Burgess, E., Falls, T. J., De Silva, N., Tsang, J., Howe, G. A., Bourgeois-Daigneault, M. C., Conrad, D. P., Daneshmand, M., Breitbach, C. J., Kirn, D. H., Raptis, L., Sad, S., Atkins, H., Huh, M. S., Diallo, J. S., Lichty, B. D., Ilkow, C. S., Le Boeuf, F., Addison, C. L., McCart, J. A. and Bell, J. C. (2015). VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell 28(2): 210-224.
   
5. Beug, S. T., Tang, V. A., LaCasse, E. C., Cheung, H. H., Beauregard, C. E., Brun, J., Nuyens, J. P., Earl, N., St-Jean, M. and Holbrook, J. (2014). Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature biotechnology 32(2): 182-190.
   
6. Ilkow, C. S., Swift, S. L., Bell, J. C. and Diallo, J. S. (2014). From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog 10(1): e1003836.
   
7. Bell, J. and McFadden, G. (2014). Viruses for tumor therapy. Cell Host Microbe 15(3): 260-265.
   
8. Cronin, M., Le Boeuf, F., Murphy, C., Roy, D. G., Falls, T., Bell, J. C. and Tangney, M. (2014). Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. Mol Ther 22(6): 1188-1197.
   
9. Bell, J. (2014). Oncolytic viruses: immune or cytolytic therapy? Mol Ther 22(7): 1231-1232.
   
10. Bell, J. C. (2014). Taming measles virus to create an effective cancer therapeutic. Mayo Clin Proc 89(7): 863-865.
    
11. Lichty, B. D., Breitbach, C. J., Stojdl, D. F. and Bell, J. C. (2014). Going viral with cancer immunotherapy. Nat Rev Cancer 14(8): 559-567.
    
12. Vaha-Koskela, M. J., Le Boeuf, F., Lemay, C., De Silva, N., Diallo, J. S., Cox, J., Becker, M., Choi, Y., Ananth, A., Sellers, C., Breton, S., Roy, D., Falls, T., Brun, J., Hemminki, A., Hinkkanen, A. and Bell, J. C. (2013). Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma. J Virol 87(4): 2363-2366.
    
13. Breitbach, C. J., Arulanandam, R., De Silva, N., Thorne, S. H., Patt, R., Daneshmand, M., Moon, A., Ilkow, C., Burke, J., Hwang, T. H., Heo, J., Cho, M., Chen, H., Angarita, F. A., Addison, C., McCart, J. A., Bell, J. C. and Kirn, D. H. (2013). Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res 73(4): 1265-1275.
    
14. Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., Burke, J., Lencioni, R., Hickman, T., Moon, A., Lee, Y. S., Kim, M. K., Daneshmand, M., Dubois, K., Longpre, L., Ngo, M., Rooney, C., Bell, J. C., Rhee, B. G., Patt, R., Hwang, T. H. and Kirn, D. H. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19(3): 329-336.
    
15. Bridle, B. W., Chen, L., Lemay, C. G., Diallo, J. S., Pol, J., Nguyen, A., Capretta, A., He, R., Bramson, J. L., Bell, J. C., Lichty, B. D. and Wan, Y. (2013). HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 21(4): 887-894.
    
16. Kim, M. K., Breitbach, C. J., Moon, A., Heo, J., Lee, Y. K., Cho, M., Lee, J. W., Kim, S. G., Kang, D. H., Bell, J. C., Park, B. H., Kirn, D. H. and Hwang, T. H. (2013). Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 5(185): 185ra163.
    
17. Conrad, D. P., Tsang, J., Maclean, M., Diallo, J. S., Le Boeuf, F., Lemay, C. G., Falls, T. J., Parato, K. A., Bell, J. C. and Atkins, H. L. (2013). Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. Clin Cancer Res 19(14): 3832-3843.
    
18. Le Boeuf, F.*, Batenchuk, C.*, Vaha-Koskela, M., Breton, S., Roy, D., Lemay, C., Cox, J., Abdelbary, H., Falls, T., Waghray, G., Atkins, H., Stojdl, D., Diallo, J. S., Kaern, M. and Bell, J. C. (2013). Model-based rational design of an oncolytic virus with improved therapeutic potential. Nat Commun 4: 1974.
    
19. Forbes, N. E., Abdelbary, H., Lupien, M., Bell, J. C. and Diallo, J. S. (2013). Exploiting tumor epigenetics to improve oncolytic virotherapy. Front Genet 4: 184.
    
20. Pol, J. G., Marguerie, M., Arulanandam, R., Bell, J. C. and Lichty, B. D. (2013). Panorama from the oncolytic virotherapy summit. Mol Ther 21(10): 1814-1818.
    
21. Roy, D. G. and Bell, J. C. (2013). Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virotherapy 2 47-56.
    
22. Auer, R. and Bell, J. C. (2012). Oncolytic viruses: smart therapeutics for smart cancers. Future Oncol 8(1): 1-4.
    
23. Breitbach, C. J., Thorne, S. H., Bell, J. C. and Kirn, D. H. (2012). Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594. Curr Pharm Biotechnol 13(9): 1768-1772.
    
24. Diallo, J. S., Vaha-Koskela, M., Le Boeuf, F. and Bell, J. (2012). Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains. Methods Mol Biol 797: 127-140.
    
25. Russell, S. J., Peng, K. W. and Bell, J. C. (2012). Oncolytic virotherapy. Nat Biotechnol 30(7): 658-670.
    
26. Bell, J. C. The virus that came in from the cold. Science Translational Medicine 13;138.
    
27. Rintoul, J. L., Lemay, C. G., Tai, L. H., Stanford, M. M., Falls, T. J., de Souza, C. T., Bridle, B. W., Daneshmand, M., Ohashi, P. S., Wan, Y., Lichty, B. D., Mercer, A. A., Auer, R. C., Atkins, H. L. and Bell, J. C. (2012). ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol Ther 20(6): 1148-1157.
    
28. Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J. S., Falls, T., Burns, J., Garcia, V., Kanji, F., Evgin, L., Hu, K., Paradis, F., Knowles, S., Hwang, T. H., Vanderhyden, B. C., Auer, R., Kirn, D. H. and Bell, J. C. (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20(4): 749-758.
    
29. Le Boeuf, F., Niknejad, N., Wang, J., Auer, R., Weberpals, J. I., Bell, J. C. and Dimitroulakos, J. (2012). Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection. Int J Cancer 131(3): E204-215.
    
30. Lemay, C. G., Rintoul, J. L., Kus, A., Paterson, J. M., Garcia, V., Falls, T. J., Ferreira, L., Bridle, B. W., Conrad, D. P., Tang, V. A., Diallo, J. S., Arulanandam, R., Le Boeuf, F., Garson, K., Vanderhyden, B. C., Stojdl, D. F., Lichty, B. D., Atkins, H. L., Parato, K. A., Bell, J. C.* and Auer, R. C.* (2012). Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Mol Ther 20(9): 1791-1799.( Co-senior authors*)
    
31. Breitbach, C. J., De Silva, N. S., Falls, T. J., Aladl, U., Evgin, L., Paterson, J., Sun, Y. Y., Roy, D. G., Rintoul, J. L., Daneshmand, M., Parato, K., Stanford, M. M., Lichty, B. D., Fenster, A., Kirn, D., Atkins, H. and Bell, J. C. (2011). Targeting tumor vasculature with an oncolytic virus. Mol Ther 19(5): 886-894.
    
32. Diallo, J. S., Roy, D., Abdelbary, H., De Silva, N. and Bell, J. C. (2011). Ex vivo infection of live tissue with oncolytic viruses. J Vis Exp(52).
    
33. Melcher, A., Parato, K., Rooney, C. M. and Bell, J. C. (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19(6): 1008-1016.
    
34. Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q., Nieva, J., Hwang, T. H., Moon, A., Patt, R., Pelusio, A., Le Boeuf, F., Burns, J., Evgin, L., De Silva, N., Cvancic, S., Robertson, T., Je, J. E., Lee, Y. S., Parato, K., Diallo, J. S., Fenster, A., Daneshmand, M., Bell, J. C. and Kirn, D. H. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477(7362): 99-102.
    
35. Hwang, T. H., Moon, A., Burke, J., Ribas, A., Stephenson, J., Breitbach, C. J., Daneshmand, M., De Silva, N., Parato, K., Diallo, J. S., Lee, Y. S., Liu, T. C., Bell, J. C. and Kirn, D. H. (2011). A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 19(10): 1913-1922.
    
36. Rintoul, J. L., Wang, J., Gammon, D. B., Van Buuren, N. J., Garson, K., Jardine, K., Barry, M., Evans, D. H. and Bell, J. C. (2011). A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PloS one 6(9).
    
37. Bell, J. C. (2011). Interfering with tumor pathways that augment viral oncolysis. Mol Ther 19(12): 2108-2109.
    
38. Ottolino-Perry, K., Diallo, J. S., Lichty, B. D., Bell, J. C. and McCart, J. A. (2010). Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18(2): 251-263.
    
39. Bell, J. (2010). Oncolytic viruses: an approved product on the horizon? Mol Ther 18(2): 233-234.
    
40. Evgin, L., Vaha-Koskela, M., Rintoul, J., Falls, T., Le Boeuf, F., Barrett, J. W., Bell, J. C. and Stanford, M. M. (2010). Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther 18(5): 896-902.
    
41. Diallo, J. S., Le Boeuf, F., Lai, F., Cox, J., Vaha-Koskela, M., Abdelbary, H., MacTavish, H., Waite, K., Falls, T., Wang, J., Brown, R., Blanchard, J. E., Brown, E. D., Kirn, D. H., Hiscott, J., Atkins, H., Lichty, B. D. and Bell, J. C. (2010). A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers. Mol Ther 18(6): 1123-1129.
    
42. Brun, J., McManus, D., Lefebvre, C., Hu, K., Falls, T., Atkins, H., Bell, J. C., McCart, J. A., Mahoney, D. and Stojdl, D. F. (2010). Identification of genetically modified Maraba virus as an oncolytic rhabdovirus. Mol Ther 18(8): 1440-1449.
    
43. Le Boeuf, F., Diallo, J. S., McCart, J. A., Thorne, S., Falls, T., Stanford, M., Kanji, F., Auer, R., Brown, C. W., Lichty, B. D., Parato, K., Atkins, H., Kirn, D. and Bell, J. C. (2010). Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18(5): 888-895.
    
44. Breitbach, C. J., Reid, T., Burke, J., Bell, J. C. and Kirn, D. H. (2010). Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev 21(2-3): 85-89.
    
45. De Silva, N., Atkins, H., Kirn, D. H., Bell, J. C. and Breitbach, C. J. (2010). Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. Cytokine Growth Factor Rev 21(2-3): 135-141.
    
46. Le Boeuf, F. and Bell, J. C. (2010). United virus: the oncolytic tag-team against cancer! Cytokine Growth Factor Rev 21(2-3): 205-211.
    
47. Stanford, M. M., Bell, J. C. and Vaha-Koskela, M. J. (2010). Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev 21(2-3): 177-183.
    
48. MacTavish, H., Diallo, J.-S., Huang, B., Stanford, M., Le Boeuf, F., De Silva, N., Cox, J., Simmons, J. G., Guimond, T. and Falls, T. (2010). Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One 5(12): e14462.
    
49. Bell, J. (2010). Oncolytic viruses: an approved product on the horizon? Molecular Therapy 18(2): 233.
    
50. Bell, J. and Kirn, D. (2010). Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword. Cytokine Growth Factor Rev 21(2-3): 83-84.
    
51. Parato, K. A., Lichty, B. D. and Bell, J. C. (2009). Diplomatic immunity: turning a foe into an ally. Curr Opin Mol Ther 11(1): 13-21.